Der Ophthalmologe

, Volume 103, Issue 2, pp 124–128

Adjuvante topische Interferon-α-2b-Therapie bei epithelialen Tumoren der Augenoberfläche

  • T. A. Fuchsluger
  • C. Hintschich
  • K.-P. Steuhl
  • D. Meller
Originalien

Zusammenfassung

Hintergrund

Die Wirkung von topischem Interferon-α-2b in der adjuvanten Therapie kornealer und konjunktivaler Tumoren soll evaluiert werden.

Material und Methoden

Im Rahmen einer nichtvergleichenden, prospektiven, interventionellen Fallserie erhielten 5 Patienten mit histologisch gesicherter konjunktivaler intraepithelialer Neoplasie (CIN) nach exzisionaler Biopsie und Defektdeckung mit Amnionmembran eine adjuvante Lokaltherapie mit Interferon-α-2b-Augentropfen 5-mal/Tag über 6 Wochen (1 Mio. IE/ml Intron® A, Fa. Schering). Eine In-situ-Hybridisierung des Entnahmematerials zum Nachweis humaner Papillomaviren (HPV) erfolgte in allen Fällen. Engmaschige klinische und fotografische Verlaufskontrollen wurden durchgeführt.

Ergebnisse

In der Zeit des Follow-up (13,2±4,97 Monate) bestand bei allen Patienten Rezidivfreiheit bei nur geringen Nebenwirkungen wie z. B. konjunktivaler Hyperämie nach 6-wöchiger Interferonapplikation. In einem Fall gelang ein positiver HPV-16/18-Nachweis.

Schlussfolgerung

Die Kombination von exzisionaler Biopsie mit topischer Applikation von Interferon-α-2b scheint eine wirksame und nebenwirkungsarme Methode zur Therapie konjunktivaler intraepithelialer Neoplasien zu sein. Wir ziehen diese kombinierte Vorgehensweise der ausschließlich topischen Gabe von Interferon-α-2b und den mehr destruktiven Verfahren wie Radiatio, Kryotherapie oder den Antimetaboliten (5-Fluorouracil, Mitomycin C) vor.

Schlüsselwörter

Konjunktivale intraepitheliale Neoplasie Interferon Augenoberfläche Amnionmembran Exzisionale Biopsie 

Adjuvant topical interferon-α-2b treatment in epithelial tumors of the ocular surface

Abstract

Purpose

The aim of this study was to evaluate the role of topical interferon-α-2b in the adjuvant treatment of corneal and conjunctival tumors.

Method

In this noncomparative, prospective, interventional case series, five patients with histologically proven conjunctival intraepithelial neoplasia (CIN) after primary excision and amniotic membrane transplantation were treated with interferon (IFN)-α-2b eye drops five times daily over a period of 6 weeks (1 million IU/ml Intron A, Schering). An in situ hybridization technique was used to detect human papillomavirus (HPV) in all specimens. Frequent follow-up was undertaken clinically and photographically for evidence of tumor recurrence.

Results

In the follow-up period (13.2±4,97 months) no clinical evidence of recurrence with only limited treatment side effects such as mild conjunctival hyperemia were recorded after 6 weeks of interferon. In one CIN specimen HPV 16/18 could be detected.

Conclusions

The combination of excisional biopsy and topical interferon-α-2b application seems to be an effective and safe treatment for conjunctival intraepithelial neoplasias. Therefore, we prefer this combined treatment to topical interferon-α-2b treatment alone, more destructive approaches such as radiation and cryotherapy, or treatment with antimetabolites such as 5-fluorouracil or mitomycin C.

Keywords

Conjunctival intraepithelial neoplasia Interferon Ocular surface Amniotic membrane Excisional biopsy 

Literatur

  1. 1.
    Ateenyi-Agaba C, Weiderpass E, Smet A et al. (2004) Epidermoid dysplasia verruciformis human papilloma virus types and carcinoma of the conjunctiva: a pilot study. Br J Cancer 90(9):1777–1779PubMedGoogle Scholar
  2. 2.
    Baron S, Tyring SK, Fleischmann WR et al. (1991) The interferons: mechanisms of action and clinical applications. JAMA 266:1375–1383PubMedGoogle Scholar
  3. 3.
    Berman B, Sequeira M (1995) Dermatologic uses of interferons. Curr Ther 13:699–711Google Scholar
  4. 4.
    Cerezo L, Otero J, Aragon G et al. (1990) Conjunctival intraepithelial and invasive squamous cell carcinoma treated with strontium-90. Radiother Oncol 17:191–197PubMedGoogle Scholar
  5. 5.
    Di Pascuale MA, Espana EM, Tseng SC (2004) A case of conjunctiva-cornea intraepithelial neoplasia sucessfully treated with topical mitomycin C and interferon alfa-2b in cycles. Cornea 23(1):89–92PubMedGoogle Scholar
  6. 6.
    Edwards I, Berman B, Rapini RP et al. (1992) Treatment of cutaneous squamous cell carcinomas by intralesional interferon alpha 2b therapy. Arch Dermatol 128:1486–1489PubMedGoogle Scholar
  7. 7.
    Erie JC, Campbell RJ, Leisegang TJ (1986) Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology 93:176–183PubMedGoogle Scholar
  8. 8.
    Grossniklaus HE, Green WR, Luckenbach M et al. (1987) Conjunctival lesions in adults: a clinical and histopathologic review. Cornea 6:78–116PubMedGoogle Scholar
  9. 9.
    Hu FR, Wu MJ, Kuo SH (1998) Interferon treatment for corneolimbal squamous dysplasia. Am J Ophthalmol 125(1):118–119PubMedGoogle Scholar
  10. 10.
    Isaacs A, Lindemann J (1957) Virus interferons, I. Interferon. Proc R Soc London Biol 147:258–267Google Scholar
  11. 11.
    Karp CL, Scott IU, Chang TS et al. (1996) Conjunctival intraepithelial neoplasia. Arch Ophthalmol 114:257–261PubMedGoogle Scholar
  12. 12.
    Karp CL, Moore JK, Rosa RH (2001) Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology 108(6):1093–1098PubMedGoogle Scholar
  13. 13.
    Kobayashi A, Yoshita T, Uchiyama K (2002) Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b. Jpn J Ophthalmol 46(2):215–217PubMedGoogle Scholar
  14. 14.
    Lee GA, Williams G, Hirst LW et al. (1994) Risk factors in the development of ocular surface epithelial dysplasia. Ophthalmology 101(2):360–364PubMedGoogle Scholar
  15. 15.
    Lippmann SM, Kavanagh JJ, Paredes-Espinoza M et al. (1992) 13-cisretonic acid plus interferon alpha 2-a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241–245PubMedGoogle Scholar
  16. 16.
    Maskin SL (1994) Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol 112:1145–1146PubMedGoogle Scholar
  17. 17.
    Morlet N, Gillies MC, Crouch R, Maloof A (1993) Effect of topical interferon-alpha 2b on corneal haze after excimer laser photorefractive keratectomy in rabbits. Refract Corneal Surg 9:443–451PubMedGoogle Scholar
  18. 18.
    Napora C, Cohen E, Genvert GI et al. (1990) Factors associated with CIN. Ophthal Surg 21:27–30Google Scholar
  19. 19.
    Nedelec B, Shen YJ, Ghahary A, Scott PG, Tredget EE (1995) The effect of interferon alpha 2b on the expression of cytoskeletal proteins in an in vitro model of wound contraction. J Lab Clin Med 126:474–484PubMedGoogle Scholar
  20. 20.
    Nedelec B, Shankowsky H, Scott PG, Ghahary A, Tredget EE (2001) Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha 2b. Surgery 130:789–808CrossRefGoogle Scholar
  21. 21.
    Peksayaar G, Soyturk MK, Demiryont M (1989) Long term results of cryotherapy on malignant epithelial tumors of the conjunctiva. Am J Ophthalmol 107:337–349PubMedGoogle Scholar
  22. 22.
    Pizzarello LD, Jakobiec FA (1978) Bowen’s disease of the conjunctiva: a misnomer. In: Jakobiec FA (ed) Ocular and adnexal tumors. Aesculapius, Birmingham, pp 553–571Google Scholar
  23. 23.
    Sanders N, Bedotto C (1972) Recurrent carcinoma in situ of the conjunctiva and cornea. Am J Ophthalmol 74:688–693PubMedGoogle Scholar
  24. 24.
    Schechter BA, Rand WJ, Velazquez GE et al. (2002) Treatment of conjunctival papillomata with topical interferon alfa-2b. Am J Ophthalmol 134(2):268–270CrossRefPubMedGoogle Scholar
  25. 25.
    Schechter BA, Schreir A, Nagler RS et al. (2002) Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea 21(1):6–11CrossRefPubMedGoogle Scholar
  26. 26.
    Scott IU, Karp CL, Nouvo GJ (2002) Human papillomavirus 16 and 18 expression in conjunctiva intraepithelial neoplasia. Ophthalmology 109(3):542–547CrossRefPubMedGoogle Scholar
  27. 27.
    Seitz B, Fischer M, Holbach LM et al. (1995) Differential diagnosis and prognosis of 112 excised epibulbar epithelial tumors. Klin Monatsbl Augenheilkd 207(4):239–246PubMedGoogle Scholar
  28. 28.
    Sjo NC, Heegaard S, Prause JA et al. (2001) Human papillomavirus in conjunctival papilloma. Br J Ophthalmology 85:785–787CrossRefGoogle Scholar
  29. 29.
    Smith M, Trousdale MD, Rao N et al. (1989) Lack of toxicity of a topical recombinant interferon. Cornea 8:58–61PubMedGoogle Scholar
  30. 30.
    Tabin G, Levin S, Snibson G et al. (1997) Late recurrences and the necessity for long term follow up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology 104:485–492PubMedGoogle Scholar
  31. 31.
    Takeuchi M, Tredget EE, Scott PG, Kilani RT, Ghahary A (1999) The antifibrogenic effects of liposome-encapsulated IFN-alpha 2b cream on skin wounds. J Interferon Cytokine Res 19:1413–1419CrossRefPubMedGoogle Scholar
  32. 32.
    Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A (2000) Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res 20:143–151CrossRefPubMedGoogle Scholar
  33. 33.
    Toledano Fernandez N, Garcia Saenz S, Diaz Valle D et al. (2003) Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia. Arch Soc Esp Oftalmol 78(5):265–271PubMedGoogle Scholar
  34. 34.
    Vann RR, Karp CL (1999) Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Ophthalmology 106(1):91–97CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang X, Peng D, Zheng H et al. (1997) Lack of corneal toxicity of interferon alpha-2b administered subconjunctivally after sclerectomy. Yan Ke Xue Bao 13(1):35–37PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  • T. A. Fuchsluger
    • 1
    • 3
  • C. Hintschich
    • 2
  • K.-P. Steuhl
    • 1
  • D. Meller
    • 1
  1. 1.Abteilung für Erkrankungen der vorderen Augenabschnitte des Zentrums für AugenheilkundeUniversitätsklinikumEssen
  2. 2.AugenklinikLudwig-Maximilians-UniversitätMünchen
  3. 3.Abteilung für Erkrankungen des vorderen Augenabschnitts des Zentrums für AugenheilkundeUniversitätsklinikumEssen

Personalised recommendations